Paper Details

  1. Home
  2. Paper Details

Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial.

Author: AmblerGareth, BaranowskiAndrew, GhiaiArtemis, GoebelAndreas, MaurerKonrad, McCabeCandy

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Treating long-standing complex regional pain syndrome (CRPS) is challenging and often ineffective. Early research suggests that the immune system may play a role in maintaining CRPS. Treatment with intravenous immunoglobulin (IVIG) at a low dose may significantly reduce pain in some patients.
Paper Details　
Original Abstract of the Article :
Treatment of long-standing complex regional pain syndrome (CRPS) is empirical and often of limited efficacy. Preliminary data suggest that the immune system is involved in sustaining this condition and that treatment with low-dose intravenous immunoglobulin (IVIG) may substantially reduce pain in so...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7326/0003-4819-152-3-201002020-00006

データ提供：米国国立医学図書館（NLM）

Intravenous Immunoglobulin (IVIG): A Potential Treatment for Complex Regional Pain Syndrome

Complex regional pain syndrome (CRPS) is a chronic pain condition that often poses a significant challenge for treatment. This randomized trial investigates the potential of intravenous immunoglobulin (IVIG) therapy for long-standing CRPS. The researchers examined the effectiveness of low-dose IVIG in reducing pain and improving outcomes in patients with CRPS.

IVIG May Offer Relief for Chronic Pain in CRPS

The study results suggest that IVIG treatment may offer significant pain reduction in some patients with long-standing CRPS. The findings provide evidence for the involvement of the immune system in the persistence of CRPS and the potential benefits of modulating the immune response through IVIG therapy. While further research is needed to confirm the long-term effectiveness and optimal dosage of IVIG for CRPS, this study offers promising insights into the potential of this treatment approach.

Exploring Immune-Modulating Therapies for Chronic Pain

This research emphasizes the importance of exploring immune-modulating therapies for managing chronic pain conditions like CRPS. The findings suggest that targeting the immune system may hold potential for addressing the underlying mechanisms of chronic pain. It's essential to consult with a healthcare professional to discuss the potential benefits and risks of IVIG therapy and other treatment options for CRPS.

Dr.Camel's Conclusion

Chronic pain can feel like a scorching desert, leaving you feeling lost and overwhelmed. This research suggests that IVIG therapy may be a cool oasis, offering relief from the relentless heat of chronic pain. While further research is needed to understand the full potential of IVIG for CRPS, this study provides a glimmer of hope for those seeking effective treatment options.

Date :
  1. Date Completed 2010-02-22
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20124231

DOI: Digital Object Identifier

10.7326/0003-4819-152-3-201002020-00006

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.